1221 results about "Rectal carcinoma" patented technology

The invention relates to the field of biotechnology and medicine, and more particularly to a polypeptide having the amino acid sequence SEQ ID NO: 1 and being capable of inhibiting RAS-GTPase activity, to the use of said polypeptide to produce a drug for treating stomach cancer or rectal cancer in a dose of 0.81-3.00 mg / kg, as well as to a drug based on said polypeptide for the treatment of stomach cancer or rectal cancer, and to a method for treating stomach cancer or rectal cancer by intraperitoneally administering said drug to a subject in an amount of 150 ml twice at an interval of 7 days.

The present invention is directed to the compounds of Formula (IV) inhibitors of KRAS(G12D). The inhibitors described herein can be useful in the treatment of diseases or disorders associated with KRAS(G12D), such as Lung cancer, Pancreatic cancer, Colorectal cancer et al. In particular, the invention is concerned with compounds and pharmaceutical compositions inhibiting KRAS(G12D), methods of treating diseases or disorders associated with KRAS(G12D), and methods of synthesizing these compounds.

The invention relates to the technical field of assessment and early warning systems, and particularly discloses a rectal cancer operation risk assessment and early warning system based on multi-modal data fusion, which comprises a multi-modal data acquisition module, a data preprocessing module, a cross-modal fusion module, a dynamic risk assessment module, an intelligent early warning module and a system self-checking module. By integrating multi-modal data and dynamically allocating weights, real-time risk updating in the whole operation period is achieved, the comprehensiveness, timeliness and precision of risk assessment are comprehensively improved by combining the grading early warning function, the autonomous detection calibration function and the risk tracing and countermeasure matching function, long-term reliable operation of the system is guaranteed, powerful support is provided for clinical decision making, and the risk assessment method is suitable for clinical decision making. The surgical risk and the complication occurrence rate are effectively reduced.

The invention belongs to the technical field of traditional Chinese medicine biology, and particularly relates to a pair of diastereoisomers in fresh bamboo juice as well as a preparation method and application of the diastereoisomers, in the diastereoisomers, a formula I is a dextroisomer and is named as (+)-fresh bamboo juice phenol A, and a formula II is a levoisomer and is named as (-)-fresh bamboo juice phenol A. According to the invention, a pair of diastereoisomer compounds (+)-fresh bamboo juice phenol A and (-)-fresh bamboo juice phenol A are successfully obtained from fresh bamboo juice, and an in-vitro cell test shows that the (+)-fresh bamboo juice phenol A has a remarkable inhibition effect on gastric cancer cells, liver cancer cells, colorectal cancer cells, bladder cancer cells and lung cancer cells of a human body; the compound can be used for preparing medicines for preventing or treating tumors, and has a wide application prospect.

The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not limited to lung cancer, pancreatic cancer, colorectal cancer, and solid tumors. In particular, the disclosure provides compounds of Formula (I):, and pharmaceutically acceptable salts thereof, wherein the substituents are as described.

The invention discloses an interpretability analysis and decision sharing verification method and system for a rectal cancer prognosis model, and relates to the field of medical artificial intelligence interpretability. The method comprises the following steps: carrying out gradient weighting class activation mapping analysis on a prognosis model to generate an image thermodynamic diagram; calculating the contribution degree of the multi-modal features by using an SHAP interpreter; an integrated visual interface is constructed, and patient data, model prediction and the explanation result are presented to a doctor together; the doctor performs independent risk assessment based on the interface information; finally, decisions of doctors and the model are compared, and model auxiliary efficiency is evaluated. Through a doctor-model decision sharing verification mechanism which is explained and innovated in a multi-level mode, the transparency and clinical credibility of the complex AI prognosis model are remarkably improved, the value of time sequence data in dynamic risk assessment can be verified, and clinical landing application of the AI model is powerfully promoted.

The invention relates to the technical field of rectal cancer prognosis prediction, in particular to a rectal cancer prognosis prediction method and device based on a multi-modal image and electronic equipment. The method comprises the following steps: firstly, acquiring an MRI image and a pathological image of a patient as original input data; respectively preprocessing the MRI image and the pathological image by adopting a double-flow heterogeneous feature extractor; then, by establishing a dynamic association mechanism, the change of the mapping relation between the two kinds of modal feature data is tracked in real time, the dynamic association mechanism can adjust the feature weight in a self-adaptive mode, and key changes in the disease progress process are effectively captured; and finally, based on the obtained dynamic association feature data, applying a pre-trained prediction model to obtain a prognosis prediction result. The MRI image and the pathological image are effectively integrated, and the accuracy of predicting the disease progress and the prediction repeatability are improved.

The invention relates to a methylation biomarker for detecting colorectal cancer or colorectal adenoma. The methylation biomarker comprises any one gene of SDC2, COL4A2 and C9H9orf50 or any combination of the SDC2, the COL4A2 and the C9H9orf50. Wherein a methylation target detection region of the SDC2 gene is a full-length region of chr8: 96494012-96494130 or a partial region of the full-length region of chr8: 96494012-96494130; a methylation target detection region of the COL4A2 gene is a full-length region of chr13: 110306814-110306983 or a part of the full-length region of the chr13: 110306814-110306983; and the methylation target detection region of the C9H9orf50 gene is the full-length region of chr9: 129620291-129620374 or a part of the full-length region of chr9: 129620291-129620374. According to the kit, methylation signals related to intestinal cancer and adenoma in excrement samples can be more accurately detected through detection in different combination modes of the three markers, the early effective diagnosis rate of colorectal cancer patients can be increased, and therefore the survival rate of the patients is increased, and prognosis is improved.

Disclosed herein is use of a combination of Compound (A) (azenosertib), or a pharmaceutically acceptable salt thereof, and a KRAS G12C inhibitor, such as sotorasib or adagrasib, or a pharmaceutically acceptable salt thereof, for treating a disease or condition, such as a colorectal, pancreatic and / or non-small cell lung cancer.

The invention discloses application of MUC12 gene in preparation of drugs for reducing rectal cancer liver metastasis, and belongs to the technical field of medical biology. According to the invention, the clear relation between colorectal cancer liver metastasis and fructose metabolism reprogramming is revealed from a molecular mechanism for the first time. The invention provides a brand-new therapeutic target and strategy by determining the brand-new transfer promoting factor MUC12 and the mediated fructose metabolism regulation effect thereof. Different from the traditional therapy only aiming at the strategies of tumor cell proliferation, blood supply and the like, the method disclosed by the invention intervenes aiming at a tumor nutrition metabolic pathway, and can weaken the metabolic adaptation and proliferation capacity of metastatic tumor cells in the liver more specifically. Experimental results show that the functions of targeted inhibition of MUC12 or downstream fructose metabolism key enzymes KHK and ALDOB thereof can significantly reduce the invasion and metastasis ability of tumor cells, and at the same time, normal growth of primary tumors cannot be significantly affected.

The invention belongs to the technical field of nuclear medicine molecular diagnosis and treatment, and discloses a modified CAIX targeting cyclic peptide, a nuclide marker and application of the modified CAIX targeting cyclic peptide in tumor diagnosis and treatment. According to the CAIX targeted cyclic peptide, a rigid bifunctional chelating agent RESCA is introduced to replace a traditional chelating agent, and a sulfonated or alkylated amino acid connector is combined, so that the enzymolysis resistance and in-vivo stability of the probe are remarkably improved. By optimizing the structure of the connector, the lipophilicity is reduced, liver and gall metabolism and non-specific uptake are reduced, and the high uptake rate of tumor target tissues is maintained. The therapeutic nuclide marker of the cyclopeptide can be used for intratumoral irradiation therapy using DOTA or NOTA in combination with an alkylated amino acid linker or an albumin ligand. Experiments show that the marker has high radiochemical purity, excellent pharmacokinetic characteristics and low kidney retention, and is suitable for precise diagnosis and targeted therapy of CAIX high expression tumors such as kidney cancer, colorectal cancer and brain glioma.

The invention provides Eubacterium mucilaginosus E11405 and an application thereof. The invention provides Eubacterium mucus E11405, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the Eubacterium mucus E11405 is CGMCC No.31231. The invention further provides a preparation method of the Eubacterium mucus E11405. The inventor of the application studies the effect and mechanism of the Eubacterium mucus E11405 in relieving the mouse colorectal cancer, and the result shows that the Eubacterium mucus E11405 has a remarkable relieving effect on the mouse colorectal cancer, and can be used as a probiotic preparation for relieving the colorectal cancer. The Eubacterium mucilaginosus E11405 provides a new strategy for prevention and treatment of colorectal cancer-based digestive tract tumors, has potential clinical application prospects, and is expected to become an effective medicine for treating colorectal cancer-based digestive tract tumors.

The invention relates to the technical field of image motion analysis, in particular to a rectal cancer radiotherapy effect dynamic monitoring system combined with iconography analysis. Determining a reference recovery index representing the recovery effect from the dimensions of edge change and area change according to the characteristic that the lesion area becomes smaller and smaller along with the better and better treatment effect; then, based on the reference recovery index and in combination with the characteristic that rectum tissue circularity can cause gradual inward contraction of a lesion area and the edge is smoother and smoother, determining a more accurate shape recovery degree representing the reference recovery index; therefore, the corrected radiotherapy recovery curve is corrected more accurately according to the shape recovery degree, and dynamic monitoring of the rectal cancer radiotherapy effect is more visual and accurate.

The invention belongs to the technical field of traditional Chinese medicine biology, and particularly relates to a phenolic compound and a preparation method and application thereof.The phenolic compound is a pair of diastereoisomers, the formula I of the phenolic compound is dextroisomer and is named as (+)-fresh bamboo juice phenol B, and the formula II of the phenolic compound is levoisomer and is named as (-)-fresh bamboo juice phenol B. A pair of diastereoisomer phenolic compounds (+)-fresh bamboo juice phenol B and (-)-fresh bamboo juice phenol B are successfully obtained from fresh bamboo juice, and the diastereoisomer phenolic compounds (+)-fresh bamboo juice phenol B and (-)-fresh bamboo juice phenol B have remarkable inhibition effects on gastric cancer cells, liver cancer cells, colorectal cancer cells, bladder cancer cells and lung cancer cells of a human body through in-vitro cell tests; the compound can be used for preparing medicines for preventing or treating tumors, and has a wide application prospect.

This invention relates to the field of anticancer drugs, and more particularly to an indole-3-aryl ketone derivative, its preparation method, and its applications. The indole-3-aryl ketone derivative is compound I-VI, which can be used to prepare drugs for the prevention and / or treatment of cancer, including at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer, and esophageal cancer. This invention screened the activity of various compounds and, for the first time, discovered that compound I-VI exhibits excellent inhibitory activity against multiple different types of human cancer cells, providing a potential option for broad-spectrum anticancer drugs.

The invention provides a rectal cancer patient management method and system based on postoperative rehabilitation data analysis, and relates to the field of postoperative rehabilitation management. And executing cross-scene associated feature anomaly recognition to extract a sensitive feature variable set as observation input of the hidden Markov model, driving a rehabilitation stage transition probability to calculate and output a state anomaly feature combination, comparing and positioning a real-time rehabilitation state, calculating and outputting a dynamic rehabilitation stage switching time window, and sending the dynamic rehabilitation stage switching time window to a medical end screen display. The technical problems in the prior art that rehabilitation stage division is extensive, rehabilitation stage switching prediction precision of individual users is insufficient, and rehabilitation management suitability is affected are solved. The technical effects of eliminating the rehabilitation stage division lag effect, performing rehabilitation stage switching accurate prediction and providing high-reliability time sequence feature support for rehabilitation management are achieved.

The invention discloses a colorectal cancer metastasis prediction method and system and a storage medium, and belongs to the technical field of medical data analysis. The method comprises the following steps: S1, preprocessing multi-modal data; s2, performing training and fine tuning on the prediction model by using the preprocessed multi-modal data; s3, performing modal fusion and external knowledge query; s4, inputting a to-be-predicted sample into the classifier to obtain a transfer prediction result, and outputting description information of the transfer prediction result by using a language encoder; s5, performing evaluation through an expert system according to professional knowledge to obtain a feedback value; when a new feedback value arrives, the prediction model carries out parameter updating through a reinforcement learning algorithm, and a prediction strategy is adjusted; model parameters are updated through a feedback value and a Bellman equation, and are gradually adjusted through multiple iterations. According to the invention, by fusing the medical image data and the electronic health record, the image information, the text information and the clinical data of the patient are effectively integrated, and the prediction precision and robustness are improved.

The invention discloses a colorectal cancer radiotherapy sensitization medicine and application thereof, belongs to the field of biological medicine, and particularly relates to a colorectal cancer radiotherapy sensitization medicine which comprises active pharmaceutical ingredients and a solvent, the active pharmaceutical ingredients comprise doxorubicin and a nitrogen-containing compound, the nitrogen-containing compound comprises quinoline-6-carbohydrazide and N-benzyloxymethyl-4-nitroimidazole, and the nitrogen-containing compound comprises quinoline-6-carbohydrazide and The colorectal cancer radiotherapy sensitization medicine disclosed by the invention focuses on a key driving gene FOXP4 for colorectal cancer radiotherapy resistance, and FOXP4 protein is degraded through a ubiquitin-proteasome way, so that not only can the sensitivity of tumor cells to radiotherapy be remarkably improved and tumor growth be inhibited, but also damage to normal tissues is reduced; moreover, the problem of drug resistance easily generated by a traditional method is effectively avoided, the research and development cost is greatly reduced, clinical transformation is accelerated, and the method has a good clinical application prospect.

The invention discloses an eRNA molecular marker for auxiliary diagnosis of colorectal cancer and application of the eRNA molecular marker, and is characterized in that the eRNA molecular marker is eRNA eCOL4A1, and the nucleotide sequence of the eRNA molecular marker is shown as SEQ ID NO.1. The invention further provides application of the eRNA molecular marker in preparation of a kit for auxiliary diagnosis of colorectal cancer, and the eRNA molecular marker comprises a fluorescent quantitative PCR specific amplification primer for detecting the eRNA eCOL4A1 in a plasma sample, the nucleotide sequence of the upstream primer is 5 '-GGGCAGTGATGTGTAGATGAGTT-3', the nucleotide sequence of the downstream primer is 5 '-TGAACATCACATGGAGC-3', and the kit has the advantages that absolute quantitative detection of target molecules and early screening and identification of colorectal cancer can be rapidly and accurately completed only by a small amount of samples, and the kit is high in sensitivity, high in accuracy and rapid in detection.

The invention provides an ORM1 and CEA protein antibody, a combination of the ORM1 and CEA protein antibody and an application of the ORM1 and CEA protein antibody in colorectal cancer diagnosis, and aims to effectively solve the problems of low affinity and specificity and poor stability of the existing antibody by optimizing the immunogen sequences of ORM1 and CEA, screening a monoclonal antibody with high affinity and high specificity, screening the optimal ORM1 and CEA antibody and combining the optimal ORM1 and CEA antibody. The kit has a wide detection range, shows an extremely high collaborative diagnosis value during combined detection, remarkably improves the diagnosis efficiency of early colorectal cancer, and has an important clinical application value.

The present invention relates to a hetero (aromatic) ring-substituted cyclic diamine compound, the preparation thereof and the use thereof in the preparation of a drug for treating and / or preventing tumors. The structural formula of the compound is as shown in (I). The compound has a significant inhibitory effect on the growth of cells of tumors such as leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophageal cancer, glioma, kidney cancer, nasopharyngeal carcinoma, liver cancer, gastric cancer and pancreatic cancer. Compared with the prior art, the compound of the present invention has a broad-spectrum anti-tumor activity, has a good effect on inhibiting tumors, and has an effect of degrading PD-L1 proteins, and is thus a PD-L1 immunomodulator.

The invention discloses a rectal cancer medical image lesion segmentation method and device based on deep learning, and aims to solve the problem that in the prior art, only a medical image is used as a single input mode, and potential semantic association among multi-mode data is neglected, so that the segmentation effect is poor. The method comprises the following steps: acquiring a to-be-detected rectal cancer medical image focus image and corresponding clinical text information, and inputting the two images into a segmentation model for processing; the clinical text information is processed through a text multi-scale feature extraction module, and target text multi-scale features are generated; encoding the text features and the medical image by using a feature encoder, and outputting target text image fusion encoding features; inputting the fusion coding feature into a scale attention module, and outputting a target text image fusion attention feature; processing the fusion attention feature and the fusion coding feature through a feature decoder to obtain a target text image decoding feature; and finally, segmenting the decoding features by using a segmentation head, and outputting a final target segmentation result.

Disclosed herein are methods and compositions for quantifying distinct prognostic and predictive contributions of tumor epithelium vs. tumor microenvironment in colorectal cancer to optimize therapy.

The present application relates to the technical field of small molecule drugs, in particular to a isoquinoline drug and its application in improving or treating digestive tract tumors, and aims to provide a compound, a pharmaceutical composition containing the compound and its application in treating colorectal cancer and gastric cancer, and provides a 3,13-position substituted berberine derivative, the drug itself has less toxicity and does not affect the growth of normal human cells, and has a good application prospect in the development of novel antitumor drugs, especially in the development of anti-digestive tract tumor drugs.

The invention discloses a rectal cancer tumor T stage differentiation labeling method based on an enhanced CT image, and relates to the field of medical image data processing, and the method comprises the following steps: a standardized manual labeling module which is used for constructing three-dimensional pixel-level labeling data of a rectal cancer tumor T stage according to a medical image and a pathological stage standard; the data set construction module is used for uniformly storing and organizing the original CT image, the annotation mask file and the matched label description document to form a structured data set which can be used for modeling; according to the rectal cancer tumor T-stage differentiation labeling method based on the enhanced CT image, a high-quality and standardized three-dimensional T-stage labeling data set is constructed, a three-dimensional pixel-level stage labeling process for the rectal cancer enhanced CT image is provided based on the AJCC eighth version tumor stage standard, the labeling content covers tumor focuses and normal intestinal wall structures around the tumor focuses, and the three-dimensional T-stage labeling data set is established. A plurality of high-annuity imaging department doctors perform independent blind marking, expert re-checking, quality rating and the like.

The invention relates to the technical field of clinical medicine, and discloses an AI prediction system for relapse after radiotherapy of local advanced rectal cancer, and the system comprises a multi-modal biological image database building module which is used for collecting clinical data, image data, radiotherapy target region and dose distribution data, radiobiological data and genomics information of a patient, integrating the data to establish a database; a feature extraction and screening module; a prediction model construction module; a model verification and optimization module; and a clinical application evaluation module. According to the invention, information of patients in multiple aspects such as clinic, image, radiotherapy target area and dose distribution, radiobiology and genomics is widely collected, and the multi-modal biological image database is integrated and established, so that various factors influencing rectum cancer relapse after radiotherapy can be comprehensively covered; a rich, accurate and comprehensive data basis is provided for subsequent accurate analysis and prediction, and the accuracy and reliability of prediction of relapse conditions after radiotherapy are improved.

The invention discloses ganoderma tsugae polysaccharide with a colorectal cancer relieving effect and a preparation method and application thereof, and belongs to the technical field of biological medicine. The ganoderma tsugae polysaccharide is prepared from mannose, glucose, galactose and fucose, the molar ratio of the mannose to the glucose to the galactose to the fucose is 3.221 to 1.414 to 80.539 to 14.826, and the molecular weight of the ganoderma tsugae polysaccharide is 7.056 kDa. It is proved that the ganoderma tsugae polysaccharide can significantly reduce the number and size of colon tumors; the pathological symptoms such as colon weight index, bleeding, crypt budding, dysplasia and hyperplasia are relieved; compared with the prior art, the ganoderma tsugae polysaccharide provided by the invention has the advantages that the ganoderma tsugae polysaccharide can obviously inhibit the levels of IFN-gamma, TGF-beta and IL-17A in colon and also can obviously inhibit the levels of IFN-gamma, TGF-beta and IL-17A in colon, and meanwhile, the level of IL-4 is improved, so that the ganoderma tsugae polysaccharide provided by the invention has an outstanding action effect in the aspect of relieving colorectal cancer, and a theoretical support is provided for developing colorectal cancer medicines with effectiveness and biological safety.

The invention relates to the field of anti-cancer drugs, in particular to an indole-3-aryl ketone derivative as well as a preparation method and application thereof. The indole-3-aryl ketone derivative is a compound I-VI, the indole-3-aryl ketone derivative can be used for preparing drugs for preventing and / or treating cancers, and the cancers comprise at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on various compounds, the fact that the compounds I-VI have excellent inhibitory activity on various different types of human cancer cells is found for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

The present disclosure provides methods and compositions, e.g., kits, for diagnosing colorectal cancer or precancerous colorectal advanced adenomas based on a subject's biomarker panels in a biological sample (e.g., a feces sample or a blood sample).

The present disclosure includes, among other things, methods, kits, and systems for determining HER2 status of cancer, e.g., a breast, gastric / gastroesophageal, colorectal, or lung cancer. In various embodiments, the present disclosure relates to the use of one or more histone modifications, chromatin accessibility, binding of one or more transcription factors, and / or DNA methylation that that are characteristic of HER2 status of cancer. In some embodiments, differential modifications and / or differential accessibility are detected and quantified at one or more genomic loci of a biological sample, e.g., in cell-free DNA (cfDNA) from a liquid biopsy sample obtained or derived from a subject with cancer. In various embodiments a determined HER2 status is useful, e.g., in selecting treatment for and / or treating a cancer, e.g., a breast, gastric / gastroesophageal, colorectal, or lung cancer.